Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

(GT)n Repeat Polymorphism in Heme Oxygenase-1 (HO-1) Correlates with Clinical Outcome after Myeloablative or Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Antigenic and immunogenic evaluation of permutations of soluble hepatitis C virus envelope protein E2 and E1 antigens

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Dancing with atrial fibrillation - How arrhythmia affects everyday life of family members: A qualitative study

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Endothelial glycocalyx and cardio-renal risk factors in type 1 diabetes

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Insulin resistance genetic risk score and burden of coronary artery disease in patients referred for coronary angiography

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Diurnal variation of magnesium and the mineral metabolism in patients with chronic kidney disease

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Lynch syndrome-associated epithelial ovarian cancer and its immunological profile

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

Allogeneic hematopoietic cell transplantation (HCT) is a treatment for various hematologic diseases where efficacy of treatment is in part based on the graft versus tumour (GVT) activity of cells in the transplant. The cytoprotective enzyme heme oxygenase-1 (HO-1) is a rate-limiting enzyme in heme degradation and it has been shown to exert anti-inflammatory functions. In humans a (GT)n repeat polymorphism regulates the expression of HO-1. We conducted fragment length analyses of the (GT)n repeat in the promotor region of the gene for HO-1 in DNA from donors and recipients receiving allogeneic myeloablative- (MA) (n = 110) or nonmyeloablative- (NMA-) (n = 250) HCT. Subsequently, we compared the length of the (GT)n repeat with clinical outcome after HCT. We demonstrated that transplants from a HO-1high donor after MA-conditioning (n = 13) is associated with higher relapse incidence at 3 years (p = 0.01, n = 110). In the NMA-conditioning setting transplantation of HO-1low donor cells into HO-1low recipients correlated significantly with decreased relapse related mortality (RRM) and longer progression free survival (PFS) (p = 0.03 and p = 0.008, respectively). Overall, our findings suggest that HO-1 may play a role for the induction of GVT effect after allogeneic HCT.

Original languageEnglish
JournalP L o S One
Volume11
Issue number12
Pages (from-to)e0168210
ISSN1932-6203
DOIs
Publication statusPublished - 2016

ID: 49656509